Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?
Clinical Liver Disease · 2022-03 · 19 (3) · 101-105
DOI: 10.1002/cld.1172 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Liver Disease, online erschienen am 03.02.2022. Verfasst von Zoe N Memel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School Boston MA. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Harvard Medical School Boston MA.
- Department of Medicine Massachusetts General Hospital Boston MA.
- Liver Center and Gastrointestinal Division Massachusetts General Hospital Boston MA.
Zitieren
APA
Memel, Z. N., Wang, J., & Corey, K. E. (2022). Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?. Clinical Liver Disease, 19(3), 101-105. https://doi.org/10.1002/cld.1172
Vancouver
Memel ZN, Wang J, Corey KE. Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?. Clinical Liver Disease. 2022;19(3):101-105. doi:10.1002/cld.1172
BibTeX
@article{Memel2022,
author = {Memel, Zoe N and Wang, Jeffrey and Corey, Kathleen E},
title = {Intermittent Fasting as a Treatment for Nonalcoholic Fatty Liver Disease: What Is the Evidence?},
journal = {Clinical Liver Disease},
year = {2022},
volume = {19},
number = {3},
pages = {101--105},
doi = {10.1002/cld.1172}
}
EUVIMED